Ann: Kazia share purchase plan, page-4

The last SPP was 20 November 2018.
Fast forward, Paxalisib is about to enter a Phase 111 registration trial with ongoing discussions on partnering with big pharma.
Further interim data on our Glioblastoma Phase 11 trial in 2H 2020.
Wait, there is more interim data from the other Paxalisib trials.
The Company has today issued 18,041,667 fully paid ordinary shares (New Shares)under a placement to professional and sophisticated investors at an issue price of A$0.40per New Share.
Investors interest in the US as well.
That is why I will be taking up the 75,000 share offer!

Good luck if you have a better investment opportunity in these uncertain times.

Regards.